Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.
When the letter from Eli Lilly and Company arrived in June 2020, Nicholas Gnadt knew a problem was brewing.
The drug maker had written to say that its Cialis erectile dysfunction pill would no longer be sold at a discount to safety-net hospitals and clinics, which serve low-income populations...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
